

*(S) 21-24* 23. (New) The method of claim <sup>36</sup> 7, in which the effective dose of interferon is administered in a plurality of smaller doses over a period of time sufficient to elicit a response equivalent to that of a single dose.

*C* 24. (New) The method of claim <sup>36</sup> 7, in which an effective dose of interferon is administered continuously over a period of time sufficient to elicit a response equivalent to that of a single dose.

*C* 25. (New) The method of claim <sup>36</sup> 7, wherein the interferon comprises a Type I interferon.

*C* 26. (New) The method of claim 25, wherein the interferon is selected from the group consisting of IFN- $\alpha$ , IFN- $\beta$ , IFN- $\omega$ , consensus IFN, and mixtures thereof.

*C* 27. (New) The method of claim 26, wherein the IFN- $\alpha$  comprises recombinant IFN- $\alpha$ .

*C* 28. (New) The method of claim <sup>36</sup> 7, wherein the interferon comprises a Type II interferon.

*C* 29. (New) The method of claim 28, wherein the Type II interferon comprises IFN- $\gamma$ .

*C 2 C 30* 30. (New) The method of claim <sup>36</sup> 7, wherein the dose of interferon is from about  $20 \times 10^6$  IU to about  $1000 \times 10^6$  IU of interferon.

*C* 31. (New) The method of claim <sup>36</sup> 7, wherein the dose of interferon is from about  $20 \times 10^6$  IU to about  $500 \times 10^6$  IU of interferon.

*C* 32. (New) The method of claim <sup>36</sup> 7, wherein the dose of interferon is from about  $50 \times 10^6$  IU to about  $500 \times 10^6$  IU of interferon.

*C* 33. (New) The method of claim <sup>36</sup> 7, wherein the viral infection is selected from the group consisting of rhinovirus, influenza, herpes varicella, herpes zoster, dengue fever, viral encephalitis, haemorrhagic fever, genital herpes, equine morbillivirus, hepatitis B, hepatitis C, hepatitis D, CMV, HIV, HPV, HSV-1 and HSV-2.

34. (New) The method of claim 33, wherein viral encephalitis is selected from the group consisting of measles virus encephalitis, Murray Valley encephalitis, Japanese B encephalitis, tick-borne encephalitis and Herpes encephalitis.

35. (New) The method of claim 33, wherein haemorrhagic fever is selected from the group consisting of Ebola virus, Marburg virus, Lassa fever, and Hanta virus infections.--

#### REMARKS

New claims 21-35 find support in the originally filed application and claims. New Claims 21-24 find support, for example, at page 12, lines 20-25. New Claims 25-29 find support, for example, at page 7,